
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc. demonstrated strong growth, with its Point of Care (POC) and formulary offerings increasing by over 100% during the recent buying season, which signifies robust demand for its services among medical professionals. The company's shares have shown resilience, edging up 3.2% since September 8, reflecting positive investor sentiment following a recent memorandum. Furthermore, the second quarter guidance appears not only achievable but also likely to exceed expectations, aided by enhanced visibility and increased upfront buying associated with their expanded product offerings.
Bears say
Doximity is facing a challenging financial outlook due to uncertainty in the economic environment, which has prompted its pharmaceutical clients to revise guidance downward for fiscal years 2023 and 2024. The company's shares are perceived as expensive when compared to its software peers, adding pressure in a context where investor expectations are already high. Furthermore, any failure to meet performance expectations or to increase guidance may lead to increased volatility and could be interpreted negatively by the market.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares